|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC00342 |
Gene summary for LINC00342 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC00342 | Gene ID | 150759 |
| Gene name | long intergenic non-protein coding RNA 342 | |
| Gene Alias | NCRNA00342 | |
| Cytomap | 2q11.1 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 150759 | LINC00342 | HCC1_Meng | Human | Liver | HCC | 2.26e-08 | -5.89e-03 | 0.0246 |
| 150759 | LINC00342 | HCC2_Meng | Human | Liver | HCC | 3.89e-32 | 4.56e-01 | 0.0107 |
| 150759 | LINC00342 | HCC1 | Human | Liver | HCC | 7.24e-03 | 2.52e+00 | 0.5336 |
| 150759 | LINC00342 | HCC2 | Human | Liver | HCC | 1.07e-09 | 2.39e+00 | 0.5341 |
| 150759 | LINC00342 | HCC5 | Human | Liver | HCC | 1.47e-08 | 2.10e+00 | 0.4932 |
| 150759 | LINC00342 | RNA-P17T-P17T-6 | Human | Lung | IAC | 2.62e-03 | 8.64e-01 | 0.3385 |
| 150759 | LINC00342 | RNA-P18T-P18T-2 | Human | Lung | IAC | 1.13e-02 | 1.23e+00 | 0.1129 |
| 150759 | LINC00342 | RNA-P18T-P18T-4 | Human | Lung | IAC | 1.13e-02 | 1.25e+00 | 0.1024 |
| 150759 | LINC00342 | RNA-P18T-P18T-6 | Human | Lung | IAC | 2.07e-02 | 1.08e+00 | 0.0856 |
| 150759 | LINC00342 | RNA-P18T-P18T-8 | Human | Lung | IAC | 1.22e-04 | 1.33e+00 | 0.1151 |
| 150759 | LINC00342 | RNA-P3T-P3T-1 | Human | Lung | IAC | 3.41e-12 | 9.16e-01 | 0.1829 |
| 150759 | LINC00342 | RNA-P3T-P3T-2 | Human | Lung | IAC | 7.75e-08 | 7.40e-01 | 0.1835 |
| 150759 | LINC00342 | RNA-P3T-P3T-4 | Human | Lung | IAC | 2.69e-16 | 9.70e-01 | 0.1859 |
| 150759 | LINC00342 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.25e-03 | 6.68e-01 | -0.0876 |
| 150759 | LINC00342 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 6.46e-03 | 5.66e-01 | -0.0822 |
| 150759 | LINC00342 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.51e-03 | 5.05e-01 | -0.0809 |
| 150759 | LINC00342 | HTA12-23-1 | Human | Pancreas | PDAC | 5.51e-04 | 5.35e-01 | 0.3405 |
| 150759 | LINC00342 | HTA12-25-1 | Human | Pancreas | PDAC | 2.80e-07 | 8.69e-01 | 0.313 |
| 150759 | LINC00342 | HTA12-26-1 | Human | Pancreas | PDAC | 8.35e-06 | 4.29e-01 | 0.3728 |
| 150759 | LINC00342 | HTA12-29-1 | Human | Pancreas | PDAC | 5.43e-26 | 6.33e-01 | 0.3722 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |